MARKET NEWS

Catalent to Open New Clinical Supply Facility in San Diego
PCI Strengthens Position in Europe With Investment in Ireland 
Fate Therapeutics Announces FDA Clearance of IND Application
Krystal Biotech Announces Initiation of Phase 1/2 Study
Atossa Genetics Announces Completion of Enrollment & Dosing in Phase 1 Clinical Trial 
Innovent & Lilly Set to Transform Diabetes Medication as Clinical Trials Begin
Apellis Dosed First Patient in Phase 3 Study
Passage Bio Closes $110-Million Series B Financing

  FEATURED EDITORIAL

  COMPANY PROFILE

Frontida BioPharm, Inc. is a leading provider of  product development and manufacturing services for both small and large biotech, pharmaceutical, and consumer health companies. Combining the rich heritage of resources from URL/Mutual Pharmaceuticals in Philadelphia, PA, and Aurora, IL, with the development expertise from Frontage Laboratories and the region’s best pharmaceutical companies, Frontida is helping our partners reach the market faster, ensuring robust product performance and on-time supply of clinical and commercial products. Our 300,000-sq-ft manufacturing facilities supply prescription and OTC products, Highly Potent Active Ingredient (HPAI) products, Fixed-dose Combination Products, and DEA schedules II–V products. Click here for more.

  EXCLUSIVE ONLINE CONTENT

2019 Analytical Testing in Drug Development eBook - Regulations Help Propel Testing Market

2019 Analytical Testing in Drug Development eBook - Regulations Help Propel Testing Market

This e-Book showcases the various types of services that leading testing companies offer and how they are helping industry comply with regulations to get their products approved and commercialized.

Nkarta Therapeutics Raises 4 Million in Series B Financing to Advance Multiple Programs Into Clinical Trials

Nkarta Therapeutics Raises $114 Million in Series B Financing to Advance Multiple Programs Into Clinical Trials

This financing is intended to support two clinical trial programs of NKX101, Nkarta’s allogenic NK cell therapy targeting NKG2D, in patients with either…..

Global Hemophilia A & B Market Set to Reach .3 Billion by 2028

Global Hemophilia A & B Market Set to Reach $9.3 Billion by 2028

The hemophilia A and B market is expected to grow from $7 billion in 2018 to $9.3 billion by 2028 across the eight major markets (8MM) at a compound annual growth rate (CAGR) of…….

Foamix Announces New US Patent That Expires in 2037

Foamix Announces New US Patent That Expires in 2037

Foamix Pharmaceuticals Ltd. recently announced the US Patent and Trademark Office has issued US Patent No. 10,398,641 covering a method of treating…….

Co-Processed Excipient for Direct Compression Designed for Orally Disintegrating Tablets

Co-Processed Excipient for Direct Compression Designed for Orally Disintegrating Tablets

Developing ODTs is a worldwide trend. In recent years, new excipients and excipient blends have enabled manufacturers to produce ODTs using conventional equipment, ie, blenders and tablet presses. One such product is GRANFILLER-D………

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

September 18 – Lyophilization Manufacturing
September 25 – Excipients